245 related articles for article (PubMed ID: 25267585)
21. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
[TBL] [Abstract][Full Text] [Related]
23. TERT promoter mutations in primary liver tumors.
Nault JC; Zucman-Rossi J
Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
[TBL] [Abstract][Full Text] [Related]
24. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.
Fujimoto A; Furuta M; Shiraishi Y; Gotoh K; Kawakami Y; Arihiro K; Nakamura T; Ueno M; Ariizumi S; Nguyen HH; Shigemizu D; Abe T; Boroevich KA; Nakano K; Sasaki A; Kitada R; Maejima K; Yamamoto Y; Tanaka H; Shibuya T; Shibata T; Ojima H; Shimada K; Hayami S; Shigekawa Y; Aikata H; Ohdan H; Marubashi S; Yamada T; Kubo M; Hirano S; Ishikawa O; Yamamoto M; Yamaue H; Chayama K; Miyano S; Tsunoda T; Nakagawa H
Nat Commun; 2015 Jan; 6():6120. PubMed ID: 25636086
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection.
Chen YL; Jeng YM; Chang CN; Lee HJ; Hsu HC; Lai PL; Yuan RH
Int J Surg; 2014; 12(7):659-65. PubMed ID: 24866078
[TBL] [Abstract][Full Text] [Related]
26. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
[TBL] [Abstract][Full Text] [Related]
27. Frequency of TERT Promoter Mutations in Prostate Cancer.
Stoehr R; Taubert H; Zinnall U; Giedl J; Gaisa NT; Burger M; Ruemmele P; Hurst CD; Knowles MA; Wullich B; Hartmann A
Pathobiology; 2015; 82(2):53-7. PubMed ID: 25997473
[TBL] [Abstract][Full Text] [Related]
28. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
29. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
31. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
32.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
33. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
34.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
35. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
[TBL] [Abstract][Full Text] [Related]
36. TERT promoter mutation in adult granulosa cell tumor of the ovary.
Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
[TBL] [Abstract][Full Text] [Related]
37. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.
Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM
J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100
[TBL] [Abstract][Full Text] [Related]
39. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma.
Huang W; Zhou W; Li C; Yang Y; Shang YK; Chen C; Zhang J; Yao R; Wang P; Wen W; Liu HQ; Wang L; Li X; Bian H; Chen ZN
Oncotarget; 2017 Apr; 8(16):26288-26297. PubMed ID: 28460432
[TBL] [Abstract][Full Text] [Related]
40. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
